In This Article:
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) instance, it's good news for shareholders.
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for Nuvectis Pharma
The Last 12 Months Of Insider Transactions At Nuvectis Pharma
In the last twelve months, the biggest single purchase by an insider was when insider Charles Mosseri-Marlio bought US$229k worth of shares at a price of US$4.70 per share. Even though the purchase was made at a significantly lower price than the recent price (US$6.80), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months insiders purchased 86.17k shares for US$446k. But they sold 2.76k shares for US$22k. In the last twelve months there was more buying than selling by Nuvectis Pharma insiders. The average buy price was around US$5.17. We don't deny that it is nice to see insiders buying stock in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Nuvectis Pharma Insiders Bought Stock Recently
At Nuvectis Pharma,over the last quarter, we have observed quite a lot more insider buying than insider selling. Insiders spent US$358k on shares. But Vice President of Finance Michael Carson sold shares worth US$22k. Insiders have spent more buying shares than they have selling, so on balance we think they are are probably optimistic.
Does Nuvectis Pharma Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Nuvectis Pharma insiders own about US$70m worth of shares (which is 54% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.